Ipamorelin is a short peptide sequence capable of binding to the ghrelin/growth hormone secretagogue receptor. It is one of the most selective growth hormone (GH) secretagogues known and has been shown in laboratory studies to have no effect on ACTH, prolactin, follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, or cortisol release.
Overview
Ipamorelin is a short peptide sequence capable of binding to the ghrelin/growth hormone secretagogue receptor. It is one of the most selective growth hormone (GH) secretagogues known and has been shown in laboratory studies to have no effect on ACTH, prolactin, follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, or cortisol release. Given its high level of specificity, ipamorelin has been of interest in research both as a therapeutic in and of itself as well as a model peptide for understanding how selectivity in receptor binding is achieved.
Ipamorelin Is Neglected in Research
Though ipamorelin does not have orphan-drug status at this time, it is still a neglected drug in research settings. Despite promising early studies, interest in ipamorelin has waned following the decision not to pursue it as a treatment for post-operative ileus. Ipamorelin has a number of benefits to offer, not just as a therapeutic, but as a tool for better understanding a number of disease states and their physiologic impacts. Ipamorelin will likely be of interest in research again, once someone jump-starts the field with new data and cutting-edge insight into the benefits of this unique peptide.
Ipamorelin exhibits moderate side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. Ipamorelin for sale at Peptide Sciences is limited to educational and scientific research only, not for human consumption. Only buy Ipamorelin if you are a licensed researcher.
Reviews
There are no reviews yet.